Worldwide Clinical Trials | Oncology

Early Phase Oncology Research Expertise

Worldwide Oncology is a specialty oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation therapies to cancer patients. Oncology clinical research, particularly early-phase development, is complex, demanding, and continually evolving. Bringing effective therapies to proof-of-concept as fast as possible is our focus because every second counts for patients with cancer and their families.

Operationalizing Early Phase Oncology Trials

Worldwide Oncology provides full-service support for Phase I through III development. With greater than 70% of our active portfolio in Phase I/II and first-in-human clinical trials, we have especially deep expertise in managing early-phase oncology research. Our experts understand the complexities of Project Optimus trial designs, how to implement cohort management on a global scale, and how to be nimble and flexible with amendments and data review to reach required milestones rapidly. Our early phase oncology site network connects us to Phase I specialty sites and principal investigators to increase success in early phase trials.

Challenges in Early Phase Oncology Trials

- Earlier dose optimization requirements
- Coordination of global cohort management, dose escalation, and expansion
- Increasingly complex study designs
- Access to more diverse patient populations
- Large global footprint required
- Greater upfront financial investment required

Worldwide Oncology's Early Phase Expertise

- Collaborative, scientific, multidisciplinary teams
- Flexible, agile approach for small biotechs
- Early Phase site network with 20+ sites across U.S., U.K. Spain, and Australia
- Global start-up and regulatory expertise
- Fluency with Project Optimus
- Drug development consulting

Exclusively Biopharma-Focused

Built to work exclusively with biopharma, our flexible processes and approach allow us to listen first, align goals, and execute with an eye toward rapid shifts when protocols amend or Breakthrough designations move a product straight from Phase I to registration.

Seasoned Oncology Experts

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, and Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

Transparent People-First Culture with Industry-Leading Retention

We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention creates program continuity, increased efficiency, and happy investigative sites.

90%
corporate retention rate

Additional Differentiators

- Flexible solutions & best-in-class technologies
- Data-centric approach with visual analytics & clinical science
- Worldwide Oncology Site Network
- Global Footprint: 4,400+ across U.S., E.U., LATAM & APAC

Active Next-Gen Oncology Experience

Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies.

Phase



Indication



Drug Class